Do interventions provide additional benefit to drug treatment of acute coronary syndromes? A call for a reserved, watchful approach.
Gulba
D C
DC
Charité-Humboldt University at Berlin, Franz Volhard Clinic, Germany. gulba@fvk-berlin.de
D000208:Acute Disease; D000789:Angina, Unstable / Q000188:drug therapy* / Q000601:surgery*; D017130:Angioplasty; D000925:Anticoagulants / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000601:surgery*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D013927:Thrombosis
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors